Roche's Sequencing Sales Decline 15 Percent in Q1 | GenomeWeb

By Julia Karow

This article has been updated from a version posted April 15 to include comments from 454's CEO.

Sequencing sales for Roche's Applied Science business fell 15 percent, measured in local currencies, in the first quarter of 2010 compared to the same period last year, the pharma and diagnostics company reported last week.

The company's sequencing revenues come from its 454 Life Sciences business, which became part of Applied Science when Roche acquired the firm in 2007.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.